Anti-Ly6G administration for 7 days reduced circulating neutrophil levels without affecting monocytes (Figure 2—figure supplement 2A,B), and treatment for 21 days markedly decreased hepatic diurnal Bmal1 and Clock expression, increased expression of Cry2, and Per2 (Figure 2—figure supplement 2C) and consequently reduced steatosis (González-Terán et al., 2016). The gene discussed is BMAL1; the disease is steatosis.